TY - JOUR
T1 - Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy
AU - Maisel, Alan S.
AU - Daniels, Lori B.
AU - Anand, Inder
AU - McCullough, Peter A.
AU - Chow, Sheryl L.
PY - 2018/4/3
Y1 - 2018/4/3
N2 - Levels of natriuretic peptides (NPs), such as B-type NP (BNP) and the N-terminal fragment of its prohormone (NT-proBNP), are well-established biomarkers for patients with heart failure (HF). Although these biomarkers have consistently demonstrated their value in the diagnosis and prognostication of HF, their ability to help clinicians in making treatment decisions remains debated. Moreover, some new HF drugs can affect concentrations of NPs, such as the prevention of BNP degradation by angiotensin receptor/neprilysin inhibitors (ARNIs), and may present a challenge in the interpretation of levels of BNP. Use of NT-proBNP measurement has been suggested in the context of ARNI therapy because its concentrations are not affected by neprilysin inhibition. As biomarkers are reconsidered in the context of ARNI therapy, cutoff levels and the effects of individual patient characteristics, such as renal function and age, on biomarker concentrations should be reassessed.
AB - Levels of natriuretic peptides (NPs), such as B-type NP (BNP) and the N-terminal fragment of its prohormone (NT-proBNP), are well-established biomarkers for patients with heart failure (HF). Although these biomarkers have consistently demonstrated their value in the diagnosis and prognostication of HF, their ability to help clinicians in making treatment decisions remains debated. Moreover, some new HF drugs can affect concentrations of NPs, such as the prevention of BNP degradation by angiotensin receptor/neprilysin inhibitors (ARNIs), and may present a challenge in the interpretation of levels of BNP. Use of NT-proBNP measurement has been suggested in the context of ARNI therapy because its concentrations are not affected by neprilysin inhibition. As biomarkers are reconsidered in the context of ARNI therapy, cutoff levels and the effects of individual patient characteristics, such as renal function and age, on biomarker concentrations should be reassessed.
KW - B-type natriuretic peptide (BNP)
KW - Heart failure (HF)
KW - N-terminal pro-B-type natriuretic peptide(NT-proBNP)
KW - biomarkers
KW - sacubitril/valsartan
UR - http://www.scopus.com/inward/record.url?scp=85044543884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044543884&partnerID=8YFLogxK
U2 - 10.1080/00325481.2018.1440873
DO - 10.1080/00325481.2018.1440873
M3 - Review article
C2 - 29596012
AN - SCOPUS:85044543884
SN - 0032-5481
VL - 130
SP - 299
EP - 307
JO - Postgraduate Medicine
JF - Postgraduate Medicine
IS - 3
ER -